Yang Shengquan, Chen Jian, Yu Yang, Li Deli, Huang Mengyuan, Yuan Li, Yin Guoyong
Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Department of Orthopaedics, The No.1 People's Hospital of Yancheng, Yancheng, Jiangsu, People's Republic of China.
Cancer Manag Res. 2018 Oct 15;10:4641-4652. doi: 10.2147/CMAR.S174143. eCollection 2018.
Long intergenic non-protein coding RNA, a regulator of reprogramming (ROR), has been found to play an oncogene role in various human malignant tumors. This meta-analysis aimed to synthesize available data to verify the association between clinical prognosis value and ROR expression level.
We performed a systematic search by using PubMed (Medline), Embase, Cochrane Library, ScienceDirect, Springer, and ISI Web of Knowledge from inception to November 15, 2017. Eleven studies with 903 patients were included in this meta-analysis according to the exclusion and inclusion criteria, and the quality of the publications was assessed by using the Newcastle-Ottawa Scale. Pooled odds ratios (OR) and hazard ratios (HR) with 95% CI were used to describe the effect.
The results showed that overexpression of ROR is positively associated with lymph node metastasis (OR=4.472, 95% CI: 3.212-6.225, Z=8.87, =0.000), tumor invasion depth (OR=9.93, 95% CI: 5.33-18.47, Z=7.24, <0.001), TNM stage (III/IV vs I/II, OR=2.96, 95% CI: 2.18-4.02, Z=6.95, <0.001), distant metastasis (OR=3.142, 95% CI: 2.187-4.513, Z=6.20, <0.001) respectively. Additionally, high expression of ROR was significantly correlated with unfavorable disease-free survival (DFS) (HR=2.74, 95% CI: 1.65-3.82, Z=4.93, =0.000) and overall survival (OS) (HR=2.09, 95% CI: 1.64-2.54, Z=9.07, <0.001). Subgroup analysis demonstrated that neither cancer type (digestive or respiratory system) nor sample size (more or less than 100) did not alter the prognostic value of ROR. Furthermore, we performed publication bias and sensitivity analysis in order to examine the stability of meta-analysis of ROR along with OS, which showed that the shape of the funnel plot was nearly symmetrical and the resulting pattern was not significantly influenced while disconnecting each suitable study.
In accordance with these results, we suggested that the overexpression of long noncoding RNA ROR could act as a novel biomarker for predicting poor prognosis in different human cancers.
长链基因间非编码RNA，即重编程调节因子（ROR），已被发现在多种人类恶性肿瘤中发挥致癌基因作用。本荟萃分析旨在综合现有数据，以验证临床预后价值与ROR表达水平之间的关联。
我们使用PubMed（Medline）、Embase、Cochrane图书馆、ScienceDirect、Springer和ISI Web of Knowledge进行了系统检索，检索时间从数据库建立至2017年11月15日。根据纳入和排除标准，本荟萃分析纳入了11项研究中的903例患者，并使用纽卡斯尔-渥太华量表评估出版物的质量。采用合并比值比（OR）和95%置信区间的风险比（HR）来描述效应。
结果显示，ROR的过表达分别与淋巴结转移（OR=4.472，95%CI：3.212-6.225，Z=8.87，P=0.000）、肿瘤浸润深度（OR=9.93，95%CI：5.33-18.47，Z=7.24，P<0.001）、TNM分期（III/IV期vs I/II期，OR=2.96，95%CI：2.18-4.02，Z=6.95，P<0.001）、远处转移（OR=3.142，95%CI：2.187-4.513，Z=6.20，P<0.001）呈正相关。此外，ROR的高表达与无病生存期（DFS）不良（HR=2.74，95%CI：1.65-3.82，Z=4.93，P=0.000）和总生存期（OS）不良（HR=2.09，95%CI：1.64-2.54，Z=9.07，P<0.001）显著相关。亚组分析表明，癌症类型（消化系统或呼吸系统）和样本量（大于或小于100）均未改变ROR的预后价值。此外，我们进行了发表偏倚和敏感性分析，以检验ROR与OS荟萃分析的稳定性，结果显示漏斗图形状近乎对称，在剔除每项合适研究时，所得模式未受到显著影响。
根据这些结果，我们认为长链非编码RNA ROR的过表达可作为预测不同人类癌症预后不良的新型生物标志物。
